Board of Directors

Rodney S. Markin, M.D., Ph.D.– Chairman

Rodney S. Markin is currently Professor of Pathology and Microbiology and Surgery, Senior Associate Dean for Clinical Affairs, College of Medicine at the University of Nebraska Medical Center and Chairman, President and CEO of UNMC Physicians (the UNMC Medical Practice). Dr. Markin’s professional and academic research interests have focused on clinical laboratory automation, which include but are not limited to, robotics, information systems, medical utilization management and outcomes optimization. Dr. Markin received his Bachelor’s Degree in chemistry with a minor in mathematics and physics from Nebraska Wesleyan University in 1977; his Doctor of Philosophy (Ph.D.-biochemistry) from the University of Nebraska-Lincoln in 1980; his Doctor of Medicine (M.D.) degree from the University of Nebraska Medical Center (Omaha) in 1983. Dr. Markin completed his residency in pathology and laboratory medicine at the University of Nebraska Medical Center. Dr. Markin is board certified in Anatomic and Clinical Pathology. Dr. Markin founded LAB-InterLink, a spin-out of the University of Nebraska Medical Center that provided products for hospital-based laboratory automation systems. He served as CEO of the company, and provided the early funding to grow the business. LAB-InterLink was sold to Cardinal Health. The intellectual property and technology is currently owned by Abbott Diagnostics. Dr. Markin is also a Director of Nebraska Surgical Solutions, Inc.

Craig J. Tuttle – Director

Craig J. Tuttle has served as President and Chief Executive Officer of Transgenomic since July 2006. Mr. Tuttle was previously the President and COO of Duke Scientific, a specialty particle technology company, and before that he was the President and CEO of Applied Biotech, Inc, a leading point-of-care rapid diagnostics manufacturer in the Apogent Technologies group. He has held management positions at Seradyn, Boehringer Mannheim, Difco Laboratories and Cetus Corporation. Mr. Tuttle holds a B.S. degree in Biochemistry from UCLA, an M.S. degree in Biochemistry from the University of Colorado, and an MBA from St. Mary’s College.

Michael McNulty - Director

Michael McNulty is currently the General Manager of Clinical Diagnostic programs at Agilent Technologies. Prior to joining Agilent Mr. McNulty was Vice President of Laboratory Operations for Berkeley HeartLabs, now a division of Celera Diagnostics. He has held executive positions in Sales and Marketing, Business Development, Operations and General Management during his 35-year career in diagnostics and clinical laboratory medicine, including 15-years as a Vice President and General Manager with SmithKline Beecham Clinical Laboratories (now Quest Diagnostics).

Jeffrey Sklar, M.D., Ph.D. – Director

Dr. Sklar is Professor of Pathology at Yale University School of Medicine. Previously, he was on the faculty of Stanford University and Harvard Medical School. He also serves as director of the Program in Molecular Diagnostic at Yale. Dr. Sklar serves on the editorial boards of numerous journals in the areas of pathology and cancer, and on scientific advisory committees: the Dana-Farber Cancer Center, Boston, MA; the Fred Hutchinson Cancer Center, Seattle, Washington; the New England Regional Primate Center; Harvard University; and the National Institutes of Health. He has served on the scientific advisory boards of numerous companies in the biotechnology field. Dr. Sklar holds an M.D. and Ph.D. from Yale University, and an M.A. (honorary) from Harvard University.

Gregory T. Sloma – Director

Mr. Sloma is currently the President of G.O., Inc., a privately held real estate company. Additionally, he sits on the board of Naturally Iowa, LLC, an organic food processor. From January 2004 through January 2006, he was the President and CFO for SpeedNet Services, Inc., a privately held Wireless Internet Provider. Prior to SpeedNet, Mr. Sloma held various positions at DTN, a publicly traded electronic information company. During his ten plus years at DTN, his positions included Vice Chairman, Director of Mergers and Acquisitions, Chief Executive Officer, President and Chief Financial Officer. Prior to joining DTN in April of 1993, Mr. Sloma spent 17 years at Deloitte & Touche, specializing in tax consulting. He started with Deloitte in 1976 and became Partner in charge of Tax, Omaha office, in 1983. Mr. Sloma received his J.D. degree, cum laude, in Business and Tax Law from the University of Nebraska in 1976, and a B.S.B.A. degree, cum laude, in Accounting from Creighton University in 1973. He is a CPA. Mr. Sloma also served on the board of West Corporation prior to it being purchased in the fall of 2006.

Antonius Schuh, Ph.D. - Director

Antonius Schuh, Ph.D., age 46, co-founded Sorrento Therapeutics, Inc. in January 2006 and has served as its Chairman since such time and as its Chief Executive Officer since November 2008. From April 2006 to September 2008 Dr. Schuh served as Chief Executive Officer of AviaraDx, Inc. (now bioTheranostics, Inc., a bioMerieux company), a molecular diagnostic testing company that is focused on clinical applications in oncology. From March 2005 to April 2006, Dr. Schuh was Chief Executive Officer of Arcturus Bioscience, Inc. (now part of MDS), a developer of laser capture microdissection and reagent systems for microgenomics. From December 1996 to February 2005, Dr. Schuh was employed by Sequenom Inc., a publicly traded diagnostic testing and genetics analysis company. He started with Sequenom as a Managing Director and was promoted to Executive Vice President, Business Development, and from May 2000 to February 2005, served as Sequenom’s President and Chief Executive Officer. He also previously served as the Head of Business Development at Helm AG, an international trading and distribution corporation for chemical and pharmaceutical products, and in medical and regulatory affairs positions with Fisons Pharmaceuticals (now part of Sanofi-Aventis). Since March 2009, Dr. Schuh has been appointed to the board of Diogenix, Inc., a privately held molecular diagnostic company, and since May 2009, Dr. Schuh has served as a director of Transgenomic, Inc., a public biotechnology company focused on genetic analysis and molecular diagnostics. Dr. Schuh is a certified pharmacist and earned his Ph.D. in pharmaceutical chemistry from the University of Bonn, Germany.